A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
PRIMARY OBJECTIVE:
I. To determine if open surgical resection is superior to thoracoscopic resection for thoracic event-free survival (tEFS) in patients with resectable oligometastatic pulmonary osteosarcoma.
SECONDARY OBJECTIVES:
I. To determine if open surgical resection is superior to thoracoscopy for event free survival (EFS) in patients with resectable oligometastatic pulmonary osteosarcoma.
II. To determine if open surgical resection is superior to thoracoscopy for overall survival (OS) in patients with resectable oligometastatic pulmonary osteosarcoma.
EXPLORATORY OBJECTIVES:
I. To compare 30-day rates of perioperative surgical complications for both open surgical resection and thoracoscopy.
II. To compare patterns of recurrence (ipsilateral and/or contralateral) in patients who undergo open or thoracoscopic resection for unilateral or bilateral pulmonary metastases.
III. To describe the use of localization techniques and its relationship with both surgical approach and pathologic findings.
IV. To assess the prognostic significance of a decision to change the post-operative treatment plan.
V. To describe the relationship between the preoperative chest computed tomography (CT) imaging, intraoperative surgical findings, and pathologic results, comparing radiological features to the presence of viable tumor.
VI. To generate well-characterized, clinically-annotated, distributable models of metastatic osteosarcoma.
VII. To collect and bank pulmonary metastatic lesions (including frozen tissues and paired metastatic lesions coming from the same patient) to facilitate study of metastatic disease and serial blood samples for future tumor profiling, germline and circulating tumor deoxyribonucleic acid (DNA) studies.
OUTLINE: Patients are randomized into 1 of 2 arms.
ARM A: Patients undergo open thoracic surgery (thoracotomy).
ARM B: Patients undergo thoracoscopy (video-assisted thoracoscopic surgery or VATS).
All patients undergo computed tomography (CT) throughout the trial. Patients may also undergo collection of tissue on study and blood throughout the trial.
After completion of study treatment, patients are followed up at 7-14 days, 4-6 weeks, and 3 months post-surgery and then every 3 months for up to 2 years.
Inclusion Criteria:
Patients must be < 50 years at the time of enrollment.
Patients must have =< 4 nodules per lung consistent with or suspicious for metastases, with at least one of which being >= 3 mm and all of which must be =< 3 cm size.
Lung nodules must be considered resectable by either open thoracotomy or thoracoscopic surgery. Determination of resectability is made by the institutional surgeon.
Patients must have a histological diagnosis of osteosarcoma.
Patients must have evidence of metastatic lung disease at the time of initial diagnosis, or at time of 1st recurrence following completion of therapy for initially localized disease.
Patients with newly diagnosed disease must have completed successful gross tumor resection for their primary tumor or surgical local control of primary tumor must be planned to be performed simultaneously with thoracic surgery.
Newly diagnosed patients must be receiving or recently completed (within 60 days) systemic therapy considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation.
Patients at time of 1st recurrence must have completed systemic therapy for their initial primary tumor, considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation.
Exclusion Criteria:
Birmingham, Alabama 35233, United States
oncologyresearch@peds.uab.edu205-638-9285
Long Beach, California 90806, United States
Palo Alto, California 94304, United States
Sacramento, California 95817, United States
Denver, Colorado 80218, United States
Washington D.C., District of Columbia 20010, United States
Gainesville, Florida 32610, United States
Atlanta, Georgia 30329, United States
Baltimore, Maryland 21287, United States
Grand Rapids, Michigan 49503, United States
Grand Rapids, Michigan 49503, United States
Norton Shores, Michigan 49444, United States
Saint Joseph, Michigan 49085, United States
Saint Joseph, Michigan 49085, United States
Minneapolis, Minnesota 55404, United States
Henderson, Nevada 89052, United States
Henderson, Nevada 89074, United States
Las Vegas, Nevada 89135, United States
Las Vegas, Nevada 89144, United States
Las Vegas, Nevada 89169, United States
Lebanon, New Hampshire 03756, United States
New Brunswick, New Jersey 08903, United States
New Hyde Park, New York 11040, United States
New York, New York 10016, United States
New York, New York 10032, United States
Syracuse, New York 13210, United States
Chapel Hill, North Carolina 27599, United States
Toledo, Ohio 43606, United States
Sioux Falls, South Dakota 57117-5134, United States
Amarillo, Texas 79106, United States
Houston, Texas 77030, United States
San Antonio, Texas 78229, United States
Burlington, Vermont 05405, United States
Spokane, Washington 99204, United States
Yakima, Washington 98902, United States
Madison, Wisconsin 53718, United States
Madison, Wisconsin 53792, United States
Sherbrooke, Quebec J1H 5N4, Canada
AKPAMC.OncologyResearchSupport@providence.org907-212-6871
research@sncrf.org702-384-0013
480-412-3100
602-546-0920
UACC-IIT@uacc.arizona.edu
501-364-7373
clinical.trials@kp.org800-398-3996
research@sncrf.org702-384-0013
clinical.trials@kp.org800-398-3996
626-564-3455
clinical.trials@kp.org800-398-3996
909-558-4050
562-933-5600
323-361-4110
clinical.trials@kp.org800-398-3996
Cancer.trial.info@cshs.org310-423-2133
Research@valleychildrens.org559-353-3000
Kpoct@kp.org877-642-4691
oncresearch@choc.org714-509-8646
ccto-office@stanford.edu800-694-0012
916-734-3089
clinical.trials@kp.org800-398-3996
858-966-5934
cancertrials@ucsf.edu877-827-3222
josh.b.gordon@nsmtp.kp.org303-764-5056
PSGResearchSharedMailbox@HCAHealthcare.com303-832-2344
860-545-9981
canceranswers@yale.edu203-785-5702
canceranswers@yale.edu203-785-5702
Allison.bruce@nemours.org302-651-5572
OncCRC_OnCall@childrensnational.org202-476-2800
molly.arnstrom@leehealth.org239-343-5333
Allison.bruce@nemours.org302-651-5572
888-624-2778
Jennifer.spinelli@orlandohealth.com321-841-5357
Allison.bruce@nemours.org302-651-5572
Ashley.Repp@jhmi.edu727-767-4784
syapchanyk@tgh.org813-844-7829
jennifer.manns@baycare.org813-357-0849
Olivia.Floyd@choa.org404-785-0232
808-983-6090
eslinget@slhs.org208-381-2774
773-880-4562
312-355-3046
cancerclinicaltrials@bsd.uchicago.edu773-702-8222
708-226-4357
ChildrensHospitalofIllinois@osfhealthcare.org309-624-4945
Claudine.Gamster@CadenceHealth.org630-315-1918
800-248-1199
samantha.mallory@unitypoint.org515-241-8912
800-237-1225
859-257-3379
CancerResource@nortonhealthcare.org502-629-5500
504-894-5377
Elisemarie.curry@ochsner.org504-842-8084
207-973-4274
clinicalresearch@mainehealth.org207-396-8670
800-888-8823
410-601-9083
jhcccro@jhmi.edu410-955-8804
301-319-2100
877-726-5130
877-442-3324
800-865-1125
CancerAnswerLine@med.umich.edu800-865-1125
crcwm-regulatory@crcwm.org616-391-1230
helpdesk@childrensoncologygroup.org
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
574-647-7370
574-647-7370
crcwm-regulatory@crcwm.org616-391-1230
616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
248-551-7695
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
crcwm-regulatory@crcwm.org616-391-1230
pauline.mitby@childrensmn.org612-813-5913
612-624-2620
855-776-0015
601-815-6700
snwq62@health.missouri.edu573-882-1960
COGResearchGroup@cmh.edu816-302-6808
314-268-4000
info@siteman.wustl.edu800-600-3606
314-251-7066
402-955-3949
unmcrsa@unmc.edu402-559-6941
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
research@sncrf.org702-384-0013
Renown-CRD@renown.org775-982-5050
research@sncrf.org702-384-0013
cancer.research.nurse@dartmouth.edu800-639-6918
551-996-2897
973-971-5900
kcovert@saintpetersuh.com732-745-8600 ext. 6163
732-235-8675
HallL@sjhmc.org973-754-2207
wburman@phs.org505-559-6113
518-262-5513
718-765-2500
718-470-3460
CancerTrials@nyulangone.org
CCTO@mssm.edu212-824-7309
cancerclinicaltrials@cumc.columbia.edu212-342-5162
212-639-7592
800-862-2215
315-464-5476
eskwak@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
aaraiza@montefiore.org718-379-6866
eskwak@montefiore.org718-379-6866
914-594-3794
NCDV.ResearchRegulatory@HCAHealthcare.com828-213-7055
cancerclinicaltrials@med.unc.edu877-668-0683
888-275-3853
eubankss@ecu.edu252-744-1015
336-713-6771
OncologyClinicalTrialsFargo@sanfordhealth.org701-323-5760
330-543-3193
cancer@cchmc.org513-636-2799
216-844-5437
TaussigResearch@ccf.org866-223-8100
Melinda.Triplet@nationwidechildrens.org614-722-6039
800-228-4055
PCIOncResearch@promedica.org419-824-1842
ou-clinical-trials@ouhsc.edu405-271-8777
503-413-2560
trials@ohsu.edu503-494-1080
Morgan_M.Horton@lvhn.org610-402-9543
cancerresearch@geisinger.edu570-271-5251
717-531-6012
215-427-8991
jean.tersak@chp.edu412-692-8570
401-444-1488
hcc-clinical-trials@musc.edu843-792-9321
Kim.Williams3@prismahealth.org864-522-4317
Kim.Williams3@prismahealth.org864-522-4317
OncologyClinicalTrialsSF@SanfordHealth.org605-312-3320
865-541-8266
referralinfo@stjude.org888-226-4343
615-342-1919
800-811-8480
TXAUS-DL-SFCHemonc.research@ascension.org512-628-1902
Crystal.DeLosSantos@dchstx.org361-694-5311
972-566-5588
canceranswerline@UTSouthwestern.edu214-648-7097
ranjan.bista@ttuhsc.edu915-298-5444
CookChildrensResearch@cookchildrens.org682-885-2103
burton@bcm.edu713-798-1354
askmdanderson@mdanderson.org866-632-6789
bridget.medina@christushealth.org210-704-2894
Vinod.GidvaniDiaz@hcahealthcare.com210-575-6240
phoresearchoffice@uthscsa.edu210-450-3800
801-585-5270
uvacancertrials@hscmail.mcc.virginia.edu434-243-6303
Stephanie.VanBebber@inova.org703-208-6650
CCBDCresearch@chkd.org757-668-7243
ctoclinops@vcu.edu
CTOclinops@vcu.edu804-628-6430
wpmccarty@carilionclinic.org540-266-6238
research@valleymed.org425-228-3440
866-987-2000
HopeBeginsHere@providence.org800-228-6618
research@multicare.org253-403-1461
melissa.a.forouhar.mil@health.mil253-968-6144
Memorial-ClinicalTrials@yvmh.org509-574-3535
cancertrialsinfo@hsc.wvu.edu304-293-7374
clinicaltrials@cancer.wisc.edu800-622-8922
clinicaltrials@cancer.wisc.edu800-622-8922
oncology.clinical.trials@marshfieldresearch.org800-782-8581
MACCCTO@mcw.edu414-955-4727
research4kids@ucalgary.ca403-220-6898
pedsoncologyresearch@ahs.ca780-407-8798
Research@iwk.nshealth.ca902-470-8520
info@thechildren.com514-412-4445
yvan.samson@umontreal.ca514-345-4931
crcinformation.chus@ssss.gouv.qc.ca819-820-6480
0800 728 436
03 364 0640